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OBJECTIVES We sought to determine whether the cardiocyte microtubule network densification charac-
teristic of animal models of severe pressure overload cardiac hypertrophy occurs in human
patients.
BACKGROUND In animal models of clinical entities causative of severe right and left ventricular (LV) pressure
overload hypertrophy, increased density of the cellular microtubule network, through viscous
loading of active myofilaments, causes contractile dysfunction that is normalized by
microtubule depolymerization. These linked contractile and cytoskeletal abnormalities, based
on augmented tubulin synthesis and microtubule stability, progress during the transition to
heart failure.
METHODS Thirteen patients with symptomatic aortic stenosis (AS) (aortic valve area 5 0.6 6 0.1 cm2)
and two control patients without AS were studied. No patient had aortic insufficiency,
significant coronary artery disease or abnormal segmental LV wall motion. Left ventricular
function was assessed by echocardiography and cardiac catheterization before aortic valve
replacement. Left ventricular biopsies obtained at surgery before cardioplegia were separated
into free and polymerized tubulin fractions before analysis. Midwall LV fractional shortening
versus mean LV wall stress in the AS patients was compared with that in 84 normal patients.
RESULTS Four AS patients had normal LV function and microtubule protein concentration; six had
decreased LV function and increased microtubule protein concentration, and three had
borderline LV function and microtubule protein concentration, such that there was an inverse
relationship of midwall LV fractional shortening to microtubule protein.
CONCLUSIONS In patients, as in animal models of severe LV pressure overload hypertrophy, myocardial
dysfunction is associated with increased microtubules, suggesting that this may be one
mechanism contributing to the development of congestive heart failure in patients with AS.
(J Am Coll Cardiol 2001;37:1080–4) © 2001 by the American College of Cardiology
The transition from compensated cardiac hypertrophy to
decompensated cardiac failure is one of the central problems
in clinical cardiology. Cardiac hypertrophy after hemody-
namic overloads fails to be functionally compensatory either
when the load increase exceeds the inherent growth capacity
of the terminally differentiated cardiac muscle cell, or
cardiocyte, to renormalize stress or when the intrinsic
contractile function per unit mass of hypertrophied myocar-
dium is less than that of normal myocardium. Thus, cardiac
compensation for an increased load may be imperfect
because of either quantitative or qualitative defects of
hypertrophied myocardium.
Our search for the basis of the qualitative defects of
hypertrophied myocardium, which are thought to underlie
the frequent deterioration of initially compensatory cardiac
hypertrophy into the congestive heart failure state, has
resulted in two novel findings (1,2). First, the contractile
abnormalities of the cardiocyte hypertrophying in response
to a severe pressure overload are accounted for to a remark-
able degree by increased density of the cellular microtubule
network, which imposes a viscous load on the shortening
sarcomeres during contraction (3), with normal contractile
function being restored when the microtubules are depoly-
merized. Second, increased microtubules, as well as nonpo-
lymerized alpha-beta-tubulin heterodimers, are present as
soon as hypertrophy is fully established, and this increase is
persistent and progressive thereafter (4,5). These findings,
which obtain both in the right and in the left ventricle (LV)
of multiple species at the levels of isolated cells (1,2,6,7),
excised tissue (8) and the intact heart in vivo (9), are based
on altered transcriptional regulation of the beta-tubulin
multigene family (10) and of the predominant microtubule-
associated protein (MAP) of the heart, MAP 4 (11).
A central goal of this work has been to determine whether
this cytoskeletal abnormality has a role in clinical heart
disease. Thus, we have proceeded in animal models from
cells, to tissue, to the heart of the intact animal and then in
clinical studies to patients with pressure overload hypertro-
phy. This study, which constitutes the step from the intact
animal to patients, was designed to address the question of
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whether increased cardiac microtubules are characteristic of
pressure overload hypertrophy in man.
METHODS
Patient selection and procedures. Thirteen symptomatic
patients with isolated valvular aortic stenosis (AS), normal
segmental LV wall motion and no significant aortic insuf-
ficiency or coronary artery disease were studied; surgical
timing was decided by the referring physician. Two control
patients had aortic reconstruction for Marfan’s syndrome;
they had no cardiac pathology as assessed by echocardiog-
raphy and cardiac catheterization. Patient recruitment,
echocardiography, cardiac catheterization and aortic valve
surgery with LV biopsy occurred at Stanford University.
The LV function data and biopsies were analyzed at the
Medical University of South Carolina.
Analysis of LV function. Left ventricular function was
evaluated as follows before surgery. Cardiac catheterization
was used to measure LV pressure and aortic valve gradient
and area, and echocardiography was used to measure LV
dimension, thickness, shortening and wall stress. Left ven-
tricular function was characterized in terms of the midwall
fractional shortening versus mean systolic stress relation-
ship. Midwall shortening was calculated from the two-shell
cylindrical model (12). Mean LV systolic stress (s) was
calculated using a cylindrical model as circumferential mid-
wall stress (12):
s 5 Pa2
[11(b2/r2)]
(b22a2)
where s was calculated as the average of stress values
measured at the three times of aortic valve opening, peak
systole and end systole and where P is LV pressure, a is LV
endocardial radius, b is LV epicardial radius, and r is LV
midwall radius. The rationale for the usage of average stress
values is the fact that the most important determinant of
ejection performance is stress throughout systole, when
ejection is occurring, rather than stress measured solely at
the end of ejection.
To calculate peak systolic stress, P was measured as peak
systolic LV pressure at the time of cardiac catheterization
and confirmed at echocardiography by sphygmomanometer
measurement of systolic arterial pressure plus the Doppler-
derived aortic gradient. The values for a, b and r were
calculated from dimensions at one-third shortening. This
method has been used in clinical (13) and experimental (14)
studies of LV function and has been validated in patients
with AS (15).
To calculate end-systolic stress, P was measured as the
aortic dicrotic notch pressure at cardiac catheterization and
confirmed during echocardiography by sphygmomanometer
measurement as the mean arterial pressure (16). The values
for a, b and r were measured from end-systolic dimensions
defined by the American Society of Echocardiography
(ASE) criteria (17).
To calculate wall stress at the instant of aortic valve
opening, P was measured as the aortic anacrotic notch
pressure at cardiac catheterization and confirmed during
echocardiography by sphygmomanometer measurement as
the mean arterial pressure. The values for a, b and r were
measured from end-diastolic dimensions (the LV remains
isovolumic between end diastole and aortic valve opening)
defined by the ASE criteria (17).
Mean systolic wall stress during ejection was, thus,
approximated by calculating the area under these three
stress-time coordinates at aortic valve opening, at peak
systole and at end systole (18).
A cohort of 84 patients not otherwise part of this study
was used to define the normal midwall fractional shortening
versus mean systolic stress relationship, given as the mean 6
95% prediction interval by the solid and dashed lines,
respectively, in Figure 1. These 84 patients (age: 59 6 15
years; gender: 44 female/42 male) will be seen in compari-
son with the patients with AS defined in Table 1 to be
slightly younger and to have the same gender distribution.
They were studied via outpatient echocardiography and
sphygmomanometer-determined arterial blood pressure in
the course of standard care, had no evidence of cardiac
disease and had normal absolute and relative LV wall
thickness, size and function. For the patients with AS and
two control patients reported in this study, LV function was
characterized with reference to the relationship thus defined
in these 84 normal patients.
Analysis of microtubule protein. After instituting cardio-
pulmonary bypass, but before instituting cold cardioplegia,
an epicardial wedge biopsy (25 to 50 mg) was taken from
the LV free wall of each of the 15 patients. The biopsy was
immediately divided into free tubulin and polymerized
tubulin (microtubule) protein fractions that were prepared
as follows. Each biopsy specimen was homogenized in 1 ml
of microtubule stabilizing buffer (19) and centrifuged at
100,000 g, 25°C for 15 min. The supernatant was saved as
the free tubulin fraction, and the pellet was resuspended at
0°C in 1 ml of microtubule depolymerization buffer (19);
after 1 h at 0°C, it was centrifuged at 100,000 g, 4°C for
15 min, and the supernatant was saved as the polymerized
tubulin fraction. Protease inhibitors (20) were used
throughout. For the subsequent 12.5% sodium dodecyl
sulfate polyacrylamide gel electrophoresis, an equal amount
of free tubulin protein as determined by a bicinchoninic acid
assay (Pierce, Rockford, Illinois) was loaded in the first lane
for each biopsy sample, and an equivalent volume of the
polymerized tubulin fraction was loaded in the second lane.
The samples were transferred to polyvinylidene difluoride
Abbreviations and Acronyms
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membranes (35 V, 75 min) and probed with a 1:3,000
dilution of a beta-tubulin monoclonal antibody (Amersham,
Arlington Heights, Illinois). Bound antibody was visualized
with a horseradish peroxidase-conjugated secondary anti-
body (Vector Labs, Burlingame, California) and enhanced
chemiluminescence (NEN Life Science Products, Boston,
Massachusetts). In all cases, a single band at 55 kDa having
the same mobility as bovine brain beta-tubulin was detected.
Densitometric quantification of the immunoblots, using a
concurrently run bovine brain beta-tubulin standard, was
carried out precisely as before (1).
Statistical analysis. Values are given as mean 6 SEM for
each data group. Statistical comparisons, defined in the legends
of the figures and tables wherein they were employed, were
said to show a significant difference at the p # 0.05 level.
RESULTS
Characteristics of the patients. The major features of the
13 patients with valvular AS are summarized in Table 1.
Medications included diuretics in five patients, beta-
adrenergic blocking agents in four patients, calcium channel
blockers in four patients and angiotensin-converting en-
zyme inhibitors in two patients. No patient suffered a
biopsy-related complication.
LV function. Figure 1A shows individual values for the
midwall fractional shortening versus mean systolic stress
relationship for the 2 control patients and 13 patients with
AS, defined in terms of 84 patients having normal cardiac
function. The 13 aortic stenosis patients self-segregated
functionally into three groups: 4 with normal LV function
(AS Normal), 3 with borderline abnormal LV function (AS
Borderline) and 6 with distinctly abnormal LV contractile
function (AS Abnormal). The summary data given in Figure
1B and Table 2 show that there is a progressive decrement in
midwall left ventricular fractional shortening when proceed-
ing from “AS Normal” through “AS Borderline” to “AS
Abnormal.”
Microtubule protein. The upper panel of Figure 2 is an
immunoblot of the free and polymerized tubulin fractions
from the myocardial biopsy of one patient from each of the
four categories identified in Figure 1. To facilitate visual
comparisons, protein loading was adjusted so that the
amount of free tubulin loaded for each patient (lanes #1)
was equal, and the volume ratio of the free to polymerized
(lanes #2) tubulin fractions loaded was held constant. Thus,
it is clear that while “Control” and “AS Normal” are
Figure 1. Left ventricular function in control patients and in patients with
AS. (Both panels) The solid and parallel dashed lines define the
relationship between midwall fractional shortening and mean systolic
stress, as well as its 95% prediction interval, and calculated using a least
squares linear regression analysis for 84 patients found not to have cardiac
pathology. The shortening-stress relationship was characterized as noted in
the “Methods” section identically for both the 84 patients used to generate
the regression analysis and for the study patients having AS. (Panel A)
Individual values for the 15 patients in this study. (Panel B) Summary data
for these same patients grouped by functional status. AS 5 aortic stenosis.
Table 1. Characteristics of Patients With Aortic Stenosis
Characteristics Values
Age (yr) 69 6 5
Gender (M/F) 7/6
Etiology, calcific/bicuspid/rheumatic 7/4/2
Aortic valve area (cm2) 0.6 6 0.1
Mean aortic valve gradient (mm Hg) 47 6 10
Symptoms, CHF/angina/syncope 11/7/2
NYHA Class, I/II/III/IV 1/5/6/1
Values are either mean 6 SEM or number of patients having a given characteristic.
CHF 5 congestive heart failure; NYHA class 5 New York Heart Association
functional class.
Table 2. LV Characteristics Versus Microtubule Protein
Group
Midwall
Fractional
Shortening (%)
Mean
Systolic Stress
(g/cm2)
Microtubule
Protein
(I.O.D.)
Control (n 5 2) 21.0 6 1.0 88.0 6 5.0 1.18 6 0.41
AS Normal (n 5 4) 19.7 6 0.4 133.3 6 5.8 0.67 6 0.24
AS Borderline (n 5 3) 16.5 6 0.3 147.3 6 11.0 6.33 6 2.89
AS Abnormal (n 5 6) 11.0 6 1.0 153.0 6 19.3 19.31 6 5.00
Values are mean 6 SEM. For each of the three LV characteristics shown here, there
was a significant (p # 0.05) trend in the data, as shown by the Spearman rank
correlation coefficient, associated with worsening clinical state.
AS 5 aortic stenosis; I.O.D. 5 integrated optical density (arbitrary units) from the
immunoblots; LV 5 left ventricular.
1082 Zile et al. JACC Vol. 37, No. 4, 2001
Cytoskeleton in Human LV Failure March 15, 2001:1080–4
equivalent, there is a progressive increase in the ratio of
polymerized/free tubulin when proceeding from “AS Nor-
mal” through “AS Borderline” to “AS Abnormal.” The lower
panel of Figure 2 that provides summary data for the immu-
noblots from all 15 patients extends this result in semiquanti-
tative terms. As shown here and in Table 2, microtubule-
incorporated tubulin, as a fraction of total protein, shows a
significant, progressive increase when proceeding from “AS
Normal” through “AS Borderline” to “AS Abnormal.”
The relationship of LV function to microtubule protein,
given in Figure 3, is inverse. Thus, in proceeding from “AS
Normal” through “AS Borderline” to “AS Abnormal,” the
successive decrements in LV systolic contractile function are
associated with successive increments in microtubule pro-
tein concentration.
DISCUSSION
The results of this study are summarized in Table 2. In
those patients with AS having an increase in the concen-
tration of myocardial microtubule protein, there is a corre-
sponding decrease in ventricular function as measured by
midwall fractional shortening, associated with significantly
increasing LV wall stress. In the clinical setting, a modality
having an acceptable therapeutic index does not exist for
removing the microtubules from interphase cells, so that we
could not establish in these patients, as we have done in
experimental models, a direct cause-and-effect relationship
between increased myocardial microtubules and decreased
myocardial contractile function. Nonetheless, these data do
allow us to conclude that, in man, as in animal models of
chronic, severe, pressure overload hypertrophy, myocardial
dysfunction is associated with an increase in the density of the
cardiocyte microtubule network, so that this cytoskeletal alter-
ation may be one mechanism that causes the development of
clinical myocardial failure in this specific hemodynamic setting.
Prevalence of the finding. The specificity of this alteration
of the extra-myofilament cytoskeleton to severe pressure
overload hypertrophy causing increased ventricular wall
stress bears emphasis. In our initial reports of this phenom-
enon (1,2), the data from an animal model with severe
pressure overload hypertrophy were compared with those
from a closely related animal model having severe volume
overload hypertrophy of an equivalent degree and duration.
Myocardial contractile dysfunction and the associated mi-
crotubule change found therein to be causative of that
contractile dysfunction were unique to the pressure-
overloaded myocardium; neither was present to any degree
whatsoever in the volume-overloaded myocardium. In sub-
sequent work by others and us described elsewhere (8), the
specificity of increased microtubule network density to the
hemodynamic setting noted above has been further estab-
lished. Thus, while these findings apply to a very important
clinical problem, they apply, based on studies to date, solely
to that particular problem.
Figure 2. Representative and summarized myocardial tubulin data for
normal patients and patients with AS. (Top) Immunoblot prepared from
left ventricular biopsies from one patient from each of the four study groups
defined in Figure 1. For comparison of the ratio of free heterodimer (lanes
#1) to polymerized microtubule (lanes #2) tubulin in the four biopsies, an
equal amount of tubulin protein was loaded for each of the free tubulin
lanes, and an equal volume of the polymerized tubulin (microtubule)
fraction was loaded for each of the polymerized tubulin lanes. (Bottom)
Summary semiquantitative tubulin data for all of the patients in the four
groups defined in Figure 1; the values were obtained from immunoblots
wherein known quantities of concurrently run pure beta-tubulin were used
as a standard, and the integrated optical density of the standards was
compared with that of the unknown samples. Statistical analysis by one
factor analysis of variance, which showed a significant (p , 0.05) F-ratio,
was followed by a Fisher protected least significant difference post-hoc test.
*p , 0.05 for difference from the value for the Control group. AS 5 aortic
stenosis.
Figure 3. The relationship of left ventricle contractile function to left
ventricle microtubule protein for all of the patients in the four groups
defined in Figure 1. AS 5 aortic stenosis.
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Validation of the finding. The validity of any newly
proposed pathophysiological mechanism of disease may be
tested in terms of the postulates originally framed by Robert
Koch (21). While, again, we are unable for practical reasons
to do this in humans, we have tested this new mechanism in
cell, tissue and whole animal experimental models of human
disease. In accordance with Koch’s first and second postu-
lates, the microtubule increase is absent in even extensive
pressure overload cardiac hypertrophy so long as muscle
function remains normal; rather, increased microtubules
develop solely in dysfunctional hypertrophied muscle and
only at the time that such dysfunction appears, at which
time microtubule depolymerization restores normal contrac-
tile function (6). In accordance with Koch’s third postulate,
chemical and physical agents, which increase microtubules
independent of hemodynamic input, were shown in these in
vitro and in vivo studies (1–11,22) to reproduce the con-
tractile and cytoskeletal abnormalities seen with severe
pressure overload cardiac hypertrophy.
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